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AbstRAct
Nanomaterials are particles or fibers with at least one of the three dimensions in the 
size range between 1 and 100 nm. Owing to unique physical and chemical properties, na-
no-sized particles (NPs) have a variety of industrial uses and are more and more preva-
lent in everyday life. However, despite the growing number of nanotechnology products, 
health risk assessment of NPs is in its early infancy. The potential adverse effects of NPs 
on prenatal development are even less well investigated. This article summarizes the 
literature on the developmental toxicity of NPs. Generally, the studies are very recent 
and include ex vivo experiments using non-mammalian species, in vitro assays (mouse 
embryonic stem cell test) and in vivo investigations using rodents. Very little has been 
published on the effects of NPs on the development and function of the human placenta 
or on the transference of NPs into the human embryo and fetus. Some limitations of 
using ex vivo and in vitro assays to predict adverse effects of NPs on human prenatal 
development are discussed in this overview. The structural and functional differences 
between the rodent and human placenta in early pregnancy and their possible relevance 
to the transplacental passage of NPs are also commented upon.
KeywoRDs: Nanoparticles; nanotoxicology; placenta; risk assessment; reproductive toxicity
Resumo
Nanomateriais são partículas ou fibras que possuem pelo menos uma das três dimen-
sões na faixa de tamanho entre 1 e 100 nm. Em virtude das suas propriedades físico-
-químicas ímpares as nano partículas têm uma variedade de usos na indústria e cada 
vez mais fazem parte do nosso cotidiano. Entretanto, apesar do número crescente de 
produtos da nanotecnologia chegando ao mercado, a avaliação dos riscos das NPs para 
saúde está na sua infância. Os efeitos nocivos das NPs sobre o desenvolvimento pré-natal 
tem sido ainda menos investigados. Este artigo sumariza a literatura sobre os efeitos das 
NPs sobre o desenvolvimento. Os estudos são em geral muito recentes e incluem expe-
rimentos ex vivo empregando invertebrados e vertebrados não-mamíferos, ensaios in 
vitro (células tronco embrionárias de camundongos) e in vivo em roedores. Muito pouco 
tem sido publicado a respeito dos efeitos das NPs na placenta e sobre a passagem das 
NPs da mãe para o embrião e feto humanos. Algumas limitações dos ensaios ex vivo e 
in vitro para evidenciar potenciais perigos das NPs para o desenvolvimento prenatal hu-
mano são discutidas nesta revisão. As diferenças de estrutura e função entre a placenta 
de roedores e a placenta humana no período inicial da gravidez e a possível relevância 
delas para a transferencia transplacentária de NPs também são comentadas.
PAlAvRAs chAve: Nanoparticulas; nanotoxicologia; placenta; avaliação de risco; 
toxicidade reprodutiva
Doi: 10.3395/vd.v1i4.114en
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Introduction
Nano (n)—from the greek “nannos” (“dwarf”)—refers to 
10-9 of a particular unit (e.g., 1 meter = 109 nanometers; 1 
liter = 109 nanoliters; 1 gram = 109 nanograms). It is one of 20 
Latin or Greek prefixes that denote decimal multiples (10n) or 
submultiples (10-n) of units in the International System of Units 
(SI). Over past decades, the prefix nano has also been used to 
define new fields of human endeavor such as the nanoscienc-
es (i.e., the study of the properties of ultra-small structures, 
materials and devices usually with dimensions ranging from 0.1 
to 100 nm) and nanotechnology (i.e., the design, characteri-
zation, production and application of structures, devices and 
systems by controlling shape and size on a nanometer scale).
The emergence of nanotechnology seems to have been in-
spired in a lecture (entitled “There’s plenty of room at the 
bottom”) delivered by Richard Phillips Feynman at the Califor-
nia Institute of Technology (Caltech, Pasadena CA) on Decem-
ber 29, 1959. Feynman, an outstanding American theoretical 
physicist and Nobel laureate, known for his contributions to 
quantum mechanics, outlined a world of novel technologies 
that would work and build machines on the smallest possible 
scale by, “maneuvering things atom by atom” at the ultimate 
frontier for miniaturization. He also noted that on such a re-
duced scale the magnitude of various physical phenomena 
might change, i.e., gravity would become less important while 
surface tension and Van der Waals attractions would become 
more important. The term nanotechnology, however, was first 
employed by Norio Taniguchi, a Japanese scientist, at a con-
ference held in 1974. Talking about semiconductor process-
es, Taniguchi defined nanotechnology as consisting of, “the 
processing of, separation, consolidation and deformation of 
materials by one atom or one molecule”. The idea of nano-
technology was further developed and popularized by Kim Eric 
Drexler in several articles and a book (“Vehicles of creation: 
the arrival of the nanotechnology era”) published in 19861,2,3,4.
In 2000, the US government created the National Nano-
technology Initiative (NNI) program, an interagency effort to 
support nanotechnology research and development it in ac-
Abbreviations
NPs, Nano-sized particles; NNI, US National Nanotechnology Initiative; MCTI, Brazilian Ministry of Science, Techno-
logy and Innovation; AUC, area under the curve; Cmax, peak plasma, serum or blood concentration; PND, postnatal day; 
GD, gestational day; QSAR, Quantitative Structure Activity Relationships; EPR, Enhanced Permeability and Retention; 
EGFR, epidermal growth factor receptor; EST, mouse embryonic stem cell test; FETAX, Frog Embryo Teratogenesis 
Assay-Xenopus; MTT assay, MTT dye (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) cytotoxicity assay 
; SWCNT, single wall carbon nanotubes; MWCNT, multiwall carbon nanotubes; SCID, severe combined immunodeficiency 
mouse strain (lacking in T and B lymphocytes and immunoglobulins).
ademic, governmental and industrial laboratories across the 
country 5. Along the same lines, in 2003, the Brazilian Ministry 
of Science, Technology and Innovation (MCTI) established a 
working group of experts to make recommendations for a gov-
ernment program to support the development of nanoscience 
and nanotechnology in Brazil. The US NNI defined nanotech-
nology as, “the understanding and control of matter of di-
mensions between approximately 1 and 100 nm, where unique 
phenomena enable novel applications”, while the Brazilian 
working group described it as, “a set of research, development 
and innovation actions that can arise from special properties 
of matter organized in structures, the dimensions of which 
are on the nanometric range scale” 6,7.
Feynman, in his seminal lecture, pointed out that, when 
the dimensions of a material are extremely reduced, approach-
ing the atomic or molecular level (nanometer scale), some of 
its physical properties may dramatically change. As dimensions 
of a material are reduced, physical properties initially remain 
unaltered, then small changes occur and when size drops be-
low a certain level (e.g., <100 nm)i drastic changes may occur. 
Some size-related changes, such as the increased surface area 
to volume ratio (or surface area per unit of mass), are gradual 
modifications that become more and more important as par-
ticle size decreases. Other changes in physical and chemical 
properties, however, occur at critical points when particle size 
reduction approaches the nanoscale. These “quantum effects” 
may involve changes in basic properties such as melting point 
and color, alterations in aerodynamic behavior and increases 
in the percentage of atoms and molecules in the material that 
are on the surface of the particle. All these changes of physical 
and chemical features may affect interactions of particles with 
biological systems and thus it seems fair to assume that the 
health effects and toxicity of materials can also be drastically 
affected by nanoscaling.
As far as safety regulation is concerned, nanotechnology 
products are usually defined by their size and not by chemical 
composition. There has been, however, some controversy over 
i The definition recommended by the European Commission states that “Nanomaterial means a natural, incidental or manufactured material containing 
particles, in an unbound state or as an aggregate or as an agglomerate and where, for 50% or more of the particles in the number size distribution, one or more 
external dimensions is in the size range 1nm–100 nm”. (2011/696/EU; Official Journal L, 275(2011) pp. 38-40). Although some consensus has been reached 
on the size range of nanomaterials (1-100 nm) (ISO 2012; http://www.iso.org/obp/ui/#home), in fact there is no clear size threshold or point for changes in 
physicochemical properties, thus the chosen 100nm cut off was an arbitrary and political choice rather than a science-based decision.
ii Occupational exposure to manufactured or engineered nanomaterials was originally regulated as “particulates not otherwise regulated” (PNOR) by US 
OSHA (2006)9.
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the definitions of the terms nanoparticle and nanoparticulate 
and how many dimensions must be less than 100 nm to meet 
such definitions8,ii. If at least one dimension (of a three-dimen-
sional structure) is on the scale of 1 to 100 nm, it is referred to 
as a “quantum well’, while if two sides are on the nanometer 
scale, it is called a “quantum wire”. If all three dimensions 
of the manufactured structure are of nanometer lengths it is 
referred to as a “quantum dot”.
Nanomedicine and nanotoxicology
Nanomedicine is a novel term designating a promising 
field that has emerged from the successful marriage of nan-
otechnology and medicine 10,11. The potential application and 
incorporation of nanotechnology into clinical practice mainly 
involves the development of new pharmaceutical products for 
treatment (e.g., nanoparticulate drug-delivery systems, nano-
engineered prosthetics for implants), diagnosis, therapy and 
monitoring of morbid conditions (e.g., biomarkers, biosensors 
and contrasts for diagnostic imaging procedures) 12,13,14.
one advantage of making use of nanotechnology in drug 
development is the possibility of overcoming the low aque-
ous solubility and poor bioavailability of some active ingre-
dients 15. The reduction of particle size leads to an increase 
in the dissolution rate of solid formulations (pills, tablets) 
and further nanosizing also enhances the rate and extent of 
active ingredient absorption (i.e., its oral bioavailability) to 
levels not attainable with typical micronized drug products 
16. In principle it is also possible to develop nanoparticulate
systems that deliver active pharmaceutical ingredients at a 
target tissue or cell (e.g., tumors).iii Nanotechnology–based 
drug delivery systems are a particularly promising therapeu-
tic approach in the area of oncology. Anticancer medicines 
are typically administered by intravenous infusion and many 
of their active ingredients are sparingly soluble. Among the 
major problems of oncologic drugs that can be successfully 
addressed by nanotechnology are: the penetration of cellular 
barriers that may otherwise inhibit arrival at the intended 
molecular target site; overcoming the multi-drug-resistance 
phenomenon, and improving the stability of the active ingre-
dient in vivo. A study by Rios-Doria et al. 17 has recently de-
scribed a novel triblock copolymer to encapsulate daunoru-
bicin (and other hydrophic anticancer drugs)iv for intravenous 
injection that improves in vivo drug stability, Cmax and AUC 
17. Rios-Doria et al‘s study 17 is a good example nanomedi-
cine contributing to improving the effectiveness of currently 
available (hydrophobic) cancer chemotherapeutic agents. An 
innovation with even more impact is the creation of antican-
cer drug formulations that can target tumor cells specifically 
thereby avoiding damage to non-malignant tissue and the as-
sociated adverse effects 18,19. One of the differences between 
malignant and non-malignant tissues that seem to make this 
target-selective anticancer drug delivery feasible is the “en-
hanced permeability and retention” (EPr)v phenomenon that 
occurs in solid tumors. Owing to deficient lymphatic drain-
age and poorly regulated angiogenesis, the unstructured and 
leaky vasculature of solid tumors allows nanoparticles to ac-
cumulate passively within the malignant tissue. Sengupta et 
al. 19 used cisplatin as a template and developed nanoparti-
cles (platinun (II) tethered to a cholesterol backbone) that 
exhibited significantly enhanced in vitro and in vivovi anti-
tumor efficacy with decreased systemic and nephro-toxici-
ty. The feasibility of this innovative approach has also been 
indicated in studies that showed that gold nanoparticles can 
be used to develop more selective and less toxic anticancer 
drugs 23,24. It was shown, for instance, that TNF-a conjugat-
ed to gold nanoparticles selectively accumulates in tumor 
tissues and by doing so allows the delivery of high doses of 
this pro-inflammatory cytokine directly to the target site, cir-
cumventing the undesirable side-effects caused by elevated 
TNF-a levels in the systemic circulation 24.
Nanotoxicology or hazard assessment of 
nanoparticles
The prefix “nano” was first added to toxicology early this 
century to define a new subcategory of this scientific disci-
pline (i.e., nanotoxicology) some years after nanotechnology 
had taken center stage 25,26,27,28,29. Nonetheless, the toxicity 
of natural and incidental ultrafine particles, including those 
on the nanoscale range, is not an entirely new topic for tox-
icologists, particularly for those who are concerned with the 
health effects of air pollution. It has long been known that the 
biological effects of inhaled aerosols and particles depend on 
their sizes and shapes so that only those smaller than 10 µm 
eventually reach the lungs. Although contributing very little to 
the overall mass of particulate air pollution, ultrafine particles 
(i.e., those <0.01 µm in diameter) are found in high concen-
trations in polluted air and several authors believe that such 
nanometer scale particles play a causal role in the detrimental 
health effects of atmospheric pollution 30,31,32,33. Studies pub-
lished in the 1990s suggested that particles <100 nm in diam-
eter caused a greater than expected toxicity (inflammatory 
response) in the lungs when compared to similar particles of 
a larger size 34,35.
iii A drug delivered directly at a therapeutic target is reminiscent of Paul Ehrlich’s concept of a “Magic Bullet” (“magische Kugel”) or the ideal therapeutic 
agent that would selectively hit the pathogen causing no undesirable effects or injury to patient’s organs and tissues.
iv in rios-Doria et al’s study17, particle sizes of encapsulated anticancer drugs were 30–80 nm.
v The general mechanism underlying the tumoritropic properties of some anticancer proteins was originally reported by Matsumara and Maeda18 who also 
introduced the idea of EPR in 1986. Further studies described that the endothelial layer of tumor blood vessels is poorly structured and has larger intercellular 
gaps (0.5–2.5 mm wide)20,21,22.
vi Anti-tumor activity was tested in vivo in murine 4T1 breast cancer and ovarian cancer models19.
vii the “t4-transatlantic think tank for toxicology” workshop36, held in 2010, at the 10th anniversary of the US NNI, discussed strategies to assess the safety of 
nanotechnology products. The t4 wokshop was organized by the Jonhs Hopkins Center for Alternatives to Animal Testing (CAAT), a center committed to the Three 
Rs (replacement, reduction and refinement of animal use).
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Developmental toxicology of nanostructured 
materials
In 2011, the report of an international workshopvii on the 
assessment of safety of nanotechnology products remarked 
that, “we are neither at the beginning of understanding the 
potential health effects, nor are we at the end, having all the 
answers the public, regulators, and policy makers require” 36. 
According to workshop attendees’ opinion, nanotoxicology was 
perhaps at “the end of the beginning” of creating a roadmap 
for a predictive testing strategy 36. As far as reproductive and 
developmental hazards are concerned (i.e., developmental 
nanotoxicology), however, we are still taking the very first 
steps towards this goal.
In fact, a search in the Pubmed data base (01 September 
2013) revealed that developmental nanotoxicology has not only 
emerged much later than the mother field of nanotechnology, 
but it has also elicited less research interest than the study 
of toxicity of nanomaterials to mature individuals (Table 1)37.
Ema et al. 38, Campagnolo et al. 39 and Sun et al. 40 in 2010, 
2012 and 2013, respectively, reviewed the literature on the re-
productive and developmental toxicity of manufactured nano-
materials, while Juch et al. addressed the interference of NPs 
with early human placental function in 2013 41. The foregoing 
reviews and the literature search in Pubmed (Table 1) con-
sistently showed that there are relatively few studies on the 
reproductive and developmental toxicity of nanoparticles and 
that “next to nothing” is known about the effects of NPs on 
the placenta during early human pregnancy.
As shown in Table 2 the developmental toxicity of several 
engineered nanomaterials has been evaluated in non-mamma-
lian animals including invertebrates (sea urchin, mollusks) and 
vertebrates (fish, frog)42,43,44,45,46,47,48,49,50,51,52,53,54,55. The embry-
onic development of zebrafish (Danio rerio) is the non-mam-
malian model most commonly used in studies of reproductive 
toxicity of NPs. Among the advantages of the zebrafish as a 
model are its fecundity, laying 200–300 eggs every 5–7 days, 
rapid embryo development and the fact that exposure of em-
bryos occurs in vitro (e.g., in multiwell plates). Since zebrafish 
embryos remain transparent throughout the majority of de-
velopment prior to hatching, the morphogenesis of the main 
organs and body structures (e.g., brain, notchord, heart, jaw, 
body segmentation) can also be observed in real time 56. Ma-
ture fish eggs and developing embryos are surrounded by an 
acellular coat, the chorion. The extent to which the chorion 
is an effective protective barrier that prevents penetration 
of distinct chemicals has not been comprehensively assessed 
so that the chorion is generally removedviii to avoid “false 
negative” results in predictive embryotoxicity assays57,58. In 
principle nanoparticles (<100 µm in one dimension) can pen-
etrate the zebrafish embryo through the chorion pore canals 
(the sizes of which are 0.5–0.7 µm in diameter). In fact, it 
was demonstrated that Ag NPs enters the chorionic space by 
passive diffusion and Brownian movement 42. However, several 
reports suggest that the chorion is an uptake barrier for SWCNP 
agglomerates 54 and some NPs such as tio2 
53 and fluorescent 
SiO2 and NPs that adhere to the surface of the chorion but do 
not enter the embryo 51.
Developmental toxicities of a variety of manufactured 
NPs, including metal (Ag, Au, Co, Cu, Ti, Zn), silica and carbon 
(SWCNTs, MWCNTs, fullerene or C60ix) NPs have been tested 
in fish (zebrafish 42,43,45,49,50,53,54,55 and Japanese Medaka fish 46), 
frog (FETAX assay 52), mollusks (oyster 50 and freshwater snails 
48), and sea urchin 44,47 embryos. As shown in Table 2, exposure 
of non-mammalian embryos to a diversity of NPs gives rise to 
hatching delays, abnormal morphogenesis, increased embryo 
mortality and other adverse developmental outcomes. In some 
cases (e.g., fullerene C60), evidence has been presented that 
the oxidative stress elicited by the NP is the underlying mech-
table 1. Number of articles dealing with nanotechnology, nanotoxicology and reproductive and developmental toxicity of 
nanoparticles found in the Pubmed data base in 2013 using different combinations of search terms.
search terms Articles (No) First published (year) Articles in 2012 (No) Articles in 2013* (No)
Nanotechnology 41,908 1991+ 5,920 3,025
Nanoparticle + toxicity 6,791 1982++ 1,528 1,013
Nanotoxicology 635 2004 237 191
Nanoparticle + pregnancy 129 1992 11 18
Nanoparticle + placenta 67 1999 17 13
Nanoparticle + developmental toxicity 91 2006 23 26
Nanotoxicology + pregnancy 9 2009 4 4
Nanotoxicology + placenta 5 2011 1 3
* As of September 1st, 2013. + A remarkable paper by Kim Drexler (Nanotechnology: the past and the future) was published in 1992. ++ A 1982 study 
by Kante et al37 with polyalkylcyanoacrylate NPs was the oldest found in Pubmed data base.
viii Under laboratory test conditions, zebrafish embryos develop normally outside their chorions. The dechorination can be achieved mechanically by using 
forceps and an enzymatic pretreatment (pronase) that makes the chorion easier to remove.
ix Fullerenes are composed entirely of carbon (e.g., 60 carbons) and may have different forms and shapes such as a hollow sphere, ellipsoid or tube. Carbon 
nanotubes are cylindrical fullerenes that are usually only a few nanometers wide and range from a micrometer to several millimeters in length.
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anism through which detrimental effects on the embryo are 
produced 59. NP stability in the assay medium, local release of 
ions and the tendency of some NPs to agglomeratex with age 
(under certain experimental conditions) should be taken into 
account when a test result is interpreted. It should be borne in 
mind that toxicokinetics and embryotoxicity of fresh (predom-
inantly singlet) and aged (predominantly agglomerated) NPs 
may differ markedly.
A key issue in creating a roadmap for a NP developmental 
toxicity testing strategy is how to balance cost-effectiveness 
and feasibility in order to evaluate an ever-growing number of 
nanotechnology products entering the market in a timely man-
ner, with assays’ or tiered test schemes’ value in predicting 
potential hazards to human embryos.
the zebrafish embryo assay has the advantage of being 
sensitive, easy and rapid to conduct and relatively inexpen-
sive. As even the time-consuming mature egg dechorination 
step allows automation, an optimized zebrafish embryo assay 
seems to be, as yet, the most suitable ex vivo test for the high 
throughput screening of developmental hazards of NPs 58.
Some authors proposed the mouse embryonic stem cell 
test (EST) as a valuable in vitro tool for screening NPs for de-
velopmental toxicity 60. Conducting both in vivo (mouse) and 
in vitro tests (EST) on the embryotoxicity of carbon nanotubes 
(SWCNTs), Pietroiusti et al. 61 concluded that the in vitro EST 
predicted in vivo results and identified oxidized SWCNTs as be-
ing more toxic than their non-oxidized (pristine) counterparts. 
Park et al. 62 also reported that the EST detected a concentra-
tion-dependent inhibition of the differentiation of stem cells 
into contracting cardiomyocites by silica NPs of 10 and 30 nm 
(primary sizes), while silica NPs of 80 and 400 nm (primary 
sizes) had no effect up to the highest concentration tested.
However, the predictive value of developmental toxicity 
tests conducted on non-mammalian species, or in mammalian 
embryonic stem cells in vitro (EST) is limited. The placenta is 
a potential target organ for NP toxicity and the interference 
of nanomaterials with placental development and function 
may eventually result in preterm delivery, prenatal growth 
retardation, congenital malformations and/or gestational 
losses 63,64,65,66,67,68.
If not secondary to placental dysfunction and/or distur-
bances in maternal homeostasis (i.e., maternal toxicity), ad-
verse effects of NPs on prenatal development arise from the 
transference of NPs via the placenta into the embryonic/fetal 
compartment (Figure 1).
In non-mammalian test systems, eggs (and the embryos 
within the eggs) are directly exposed and thus these assays 
cannot anticipate the indirect (maternally and or placentally 
mediated) effects of NPs. Moreover, to enhance test sensitivi-
ty, possible barriers to penetration of test substances into the 
egg are removed, as are the chorion in the zebrafish assay and 
the jelly coat in the FETAX (frog) test 69.xi Zebrafish and other 
non-mammalian test systems, therefore, can detect potential 
x Agglomeration of nanoparticles (enlarging the real particle size) is known to be influenced by number, concentration and other physical factors
Figure 1. Mechanisms by which nanoparticles (NPs) and NP-
-delivered drugs found in the maternal blood can penetrate the 
human placenta and reach the developing embryo or fetus. The 
interface between maternal circulation and embryonic or fetal 
blood involves the syncytiotrophoblast (ST, a multi-nucleated 
terminally differentiated syncytium formed by fusion of cyto-
trophoblast cells), the matrix or supporting connective tissue of 
the chorionic villi in which blood vessels are found (VS, villous 
stroma) and the endothelial lining (a single layer of flattened 
cells) of fetal capillaries. A- Fusion with ST membrane. Cationic 
NPs and liposomes in the maternal blood may fuse with ST mem-
brane and enter the cytoplasm where they can be disassembled 
thereby releasing their contents directly into ST cytosol. NP con-
tents then diffuse to the villous stroma and the fetal capillary 
entering its lumen. An additional possibility (not depicted in the 
Figure) is the NP or liposome to remain intact within the cyto-
plasm and be fused with the ST basal membrane (BM) thereby 
releasing its contents into the villous stroma. B – Endocytosis. NP 
might be taken by endocytosis and either be degraded (in en-
dosomes) thereby releasing their contents in the ST cytosol, or 
be transported via transcytosis to the villous stroma. Moving by 
simple diffusion the NPs (via pores between endothelial cells), 
or their contents (via both pores and endothelial cell cytoplasm) 
may then reach the lumen of the fetal capillary. C- Receptor–
mediated mechanism. Ligand-modified NPs might bind to ST 
apical membrane receptor undertaking endocytosis. They may 
either be disassembled releasing their contents into the ST cyto-
sol or be transferred by transcytosis into villous stroma. D-NP 
with certain features in terms of dimensions, charge, or surface 
composition may fail to penetrate the apical membrane of the 
ST thereby being unable to cross from the maternal to the fetal 
compartment. In any of cases of NPs that penetrate the apical 
membrane of ST (A,B,C) an additional possibility is the retention 
of the intact NPs within the ST cytoplasm.
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developmental toxicants that would not reach the mammalian 
embryo owing to the protective roles of the placenta and the 
maternal organism but, cannot detect harmful effects on the 
embryo arising from maternal toxicity and placental dysfunc-
tion. In other words, test systems (in non-mammals or in vitro) 
in which embryo exposure to NPs do not occur through the 
placenta are prone to yielding both false positive and false 
negative results with respect to potential hazards to develop-
ing mammalian/human conceptuses.
transplacental transfer and toxicity to 
mammalian embryos
Kinetic studies of classical xenobiotic compounds suggest 
that highly hydrophilic and large molecules (>1 kDa) are un-
likely to be transferred across the placenta to the concep-
tusxii. Nonetheless, as highlighted by Maynard et al. 29, due to 
abrupt size-dependent changes in interactions with biological 
systems, the toxicity of engineered NPs (an “emergent risk”) 
may arise from the unanticipated penetration of particles 
and fibers into tissues normally inaccessible to large mole-
cules and particles 29.
As shown by studies depicted in Table 3, maternal expo-
sure to a variety of manufactured NPs was associated with 
harmful effects on mouse and rat embryos 61,70,72,73,74,75,76,77,78,79,80
,81,82,83,84. In at least three studies 73,77,82,xiii, NPs were detected in 
the prenatally exposed offspring thereby indicating that tested 
NPs were transferred to the developing conceptus across the 
placenta. Blum et al. 81, however, detected NPs (CdO) in the 
placenta and maternal organs of treated mice but not in their 
fetuses. Therefore, the embryotoxic effects of CdO NPs noted 
by the authors (e.g., delayed fetal and neonatal growth) were 
probably secondary to effects on the placenta and/or maternal 
toxicity (Table 3).
Overall, the rodent studies performed to date indicate 
that the exposure of pregnant females to different types of 
NPs may result in a variety of adverse outcomes of pregnancy 
such as embryo mortality, intra-uterine growth retardation, 
structural anomalies, and altered gene expression in the pre-
natally exposed offspring (Table 3). Some studies have pro-
vided additional kinetic data suggesting that developmentally 
toxic NPs crossed the placenta so that embryos were directly 
exposed. In at least one case, however, embryotoxic effects 
of NPs seemed to have been secondary to maternal and/or 
placental toxicity 81. The absence of discernible adverse ef-
fects on embryo development even when NP exposure resulted 
in marked maternal toxicity has also been reported 79. In a 
study by Chan & Shiao 83 mouse blastocysts were exposed to 
NPs (CdSe QDs) in vitro, and then implanted into dams’ uteri. 
In this case, the authors found detrimental effects of tested 
NPs on embryo development both in vitro (e.g., blastocyst 
cell apoptosis) and in vivo after transfer and implantation of 
in vitro-exposed embryos.
Owing to interspecies differences with respect to pla-
cental structure and function, toxic effects of NPs on de-
velopment noted in rodents may not occur in humans 85 
(Tables 4,5, Figure 2). In the rat, the inverted visceral yolk 
sac (intimately apposed to the uterine tissues) is the major 
structure mediating maternal and embryonic exchanges in 
early pregnancy (GD 7.5–12) 85,86. In humans, however, there 
has been no indication that histiotrophic nutrition (via a yolk 
sac) is an important pathway for nutrient acquisition vis a vis 
chorionic villi mediated hemotrophic exchanges 86. It has been 
demonstrated that substances that inhibit rodent yolk sac 
function such as trypan blue and concanavalin A are also tera-
togenic 87,88. the previously mentioned interspecies differences 
in placental structure and function, suggest that inhibitors of 
yolk sac mediated maternal-embryonic exchanges in rodents 
are unlikely to cause similar teratogenic effects in humans. 
Although an explanation for some of the embryotoxic effects 
in Table 3, whether or not NPs affect rodent yolk sac mediated 
maternal-embryonic exchanges and the extent to which they 
do so remain largely unclear.
Currently little is known about the transplacental trans-
port of engineered NPs and whether NPs interfere with placen-
tal function in humans 64,65. Only a few studies have addressed 
these crucial questions. Myllynen et al. 67 observed that PE-
gylatedxiv gold NPs (10–30nm in diameter) did not cross (over 
a 6 h perfusion test) the ex vivo perfused human placenta in 
detectable (ICP-MS) amounts. The authors also noted that gold 
NPs were taken up by the syncytiotrophoblast cell layer (possi-
bly via non-specific endocytosis), a finding suggesting that the 
placenta may act as a sequestration organ for these NPs. Wick 
et al. 68 also used an ex vivo placental perfusion method (ap-
plied in the maternal to fetal direction for 6 h) to investigate 
transplacental transport of fluorescently labeled polysterene 
beads (sizes 50–500 nm). According to the study’s results, poly-
styrene NPs smaller than 240 nm exhibited a size-dependent 
ability to cross the placenta in the direction of the fetal circu-
lation and that transfer process was apparently saturable and 
possibly involved an endocytotic mechanism. A recent study 
by Sønnegaard-Poulsen et al. 66 using an in vitro (BeWo b30 
choriocarcinoma cell line, MTT cytotoxicity assay) and an ex 
vivo (perfused human placenta) model found that silica NPs 
decreased BeWo cell viability at concentrations higher than 
100 µg/mL. The authors also noted that the percentage of sili-
xi In the FETAX assay69 after frog egg laying, the jelly coat (a thick, sticky coating surrounding the egg) is removed by gently swirling the egg mass with 
a solution of L-cysteine. This de-jellying of embryos is undertaken to facilitate xenobiotic penetration of the egg thereby enhancing assay sensitivity to 
developmental toxicants.
xii Exceptions to this rule are large macromolecules specifically transported by the synctiotrophoblast, for example IgG (from the 13th week of human pregnancy 
onwards).
xiii In Jo et al’s study, pups underwent euthanasia on PND4 and so transference of NPs to pups via the maternal milk cannot be ruled out in this case.
xiv PEGylation is a covalent attachment of polyethylene glycol (PEG) polymer chains to NP or another molecule. The covalent attachment of PEG to a drug or 
therapeutic protein can “mask” the NP or macromolecule from the host’s immune system, increase its water solubility and hydrodynamic size (size in solution), 
and reduce its renal clearance, thereby prolonging its circulatory time.
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ca NPs reaching the fetal perfusate after 6 h was limited to 4.2 
and 4.6% for 25 and 50 nm NPs, respectively, and that NPs are 
poorly transported across BeWo cells 66.
The other side of the coin is that the selective delivery/
toxicity of NPs towards the placenta and embryo can eventu-
ally be useful for treating life-threatening medical conditions 
involving abnormal growth of the trophoblast such as ectopic 
pregnancy, choriocarcinoma and placenta accreta. In line with 
this, Kaitu’u-Lino et al. 89 employed nanocellsxv loaded with 
doxorubicin to deliver this chemotherapeutic drug to placen-
tal tissue. The authors showed that targeted NP+doxorubicin 
delivery induced marked regression of JEG-3 (choriocarcinoma 
cells) tumor xenografts in SCID mice. They also demonstrated 
that EGFR targeted NPs were readily taken up by human pla-
table 4. Some interspecies differences regarding placental morphology and function.
Feature
rodents Primates
rat mouse rhesus monkey human
gestation length (d) 22 19 166 266
implantation (gD) 5-6 5 9 6-7
implantation
early eccentric eccentric superficial interstitial
late interstitial interstitial
Shape discoid discoid bidiscoid discoid
Placenta (fetal membranes)
early inverted yolk sac inverted yolk sac chorioallantoic chorioallantoic
definitive chorioallantoic chorioallantoic chorioallantoic chorioallantoic
Implantation types: 1) superficial: chorionic sac is in contact with uterus lumen; 2) eccentric: chorionic sac is in a “pocket” partially separated from 
uterus lumen; 3) interstitial: chorionic sac is within the uterine wall losing contact with uterus lumen. Chorioallantoic placenta: formed by the chorion 
(outermost avascular membrane of embryonic vesicle) that is augmented by and receives vascularization from the allantois. Inverted yolk sac placenta: 
formed by membranes of rodent large yolk sacs, it is at times called “inverted” because outer yolk sac membranes become discontinuous at the apposition 
to the uterine wall, leaving the inner yolk sac membrane nearly in contact with the uterine lumen and epithelium. Rodents do not develop the definitive 
chorioallantoic placenta until a circulatory system is operative (i.e., in rats GD 11-11.5) whereas yolk sac placentas are not formed in primates. 
table 5. Functional differences between the inverted yolk 
sac and the chorioallantoic placenta. 
Placenta structure Functional features
inverted yolk sac 
(rodents: early pregnancy)
Mother Embryo exchanges by 
histiotrophic process; pinocytosis 
(lysosome dependent process) by yolk 
sac epithelial cells of macromolecules 
found in maternal uterus secretions 
Chorioallantoic (primates, 
and definitive in rodents, 
after GD 11-11.5 in rats)
Exchanges between maternal and 
embryo/fetus circulation by a direct 
hemotrophic process
Exchanges of nutrients through hemotrophic process of 
chorioallantoic placenta are faster and more efficient than those 
mediated by histiotrophic process of inverted yolk placenta.
Figure 2. Differences between rodents (eccentric) and humans (interstitial) regarding the mode by which placentation takes place 
in early pregnancy. Note that in the eccentric type of placentation, the chorionic sac is within a “pocket” that is partially in con-
tact with the uterine lumen, whereas in the interstitial type, the chorionic sac is entirely enveloped by the uterus wall keeping no 
contact with its lumen.
xv Kaitu’u-Lino et al 89 used bacterially derived nanospheres (400nm in diameter) known as “EnGeneIC Delivery Vehicles” (EDVs) to target the epidermal 
growth factor receptor (EGFR) and so promote trophoblast tissue specific delivery of the antineoplastic drug doxorubicin. Placental targeting was achieved 
with the presence of bispecific antibodies against EGFR on the sphere surface. Since EGFRs are highly expressed on the placenta surface, doxorubicin (an 
antiproliferative agent) was specifically delivered to the target abnormal tissue. It is of note that these EDV are larger than 100 nm in diameter, and so 
technically they do not fit the previous (arbitrary) definition of NP.
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cental explants ex vivo and then induced apoptosis and in an 
in vitro assay (JEG-3 cells) produced inhibition of cell viability 
and proliferation and enhanced apoptosis. Overall, laboratory 
results suggest that this is a feasible therapeutic approach for 
further clinical trials in female patients with abnormal tropho-
blast growth disorders.
conclusion
Although required for assessing health risks to women, the 
evaluation of the reproductive and developmental toxicity of 
NPs has not kept pace with the extraordinary expansion of the 
number and diversity of new nanotechnology products intro-
duced to everyday life in recent years.
As depicted in Tables 2 and 3, the experimental stud-
ies conducted as yet have provided indications that several 
types of NPs might have adverse effects on the embryonic 
development of invertebrates (sea urchin, oyster, fresh-
water snail), non-mammalian vertebrates (fish, frog) and 
mammals (rats, mice). Furthermore, a few rodent studies 
also found evidence that some developmentally toxic NPs 
pass through the placenta and reach the embryo/fetal com-
partment. However, differences in the development and 
function of the placenta in early pregnancy (e.g., inverted 
yolk sac in rats versus chorionic villi in humans) make the 
extrapolation of results from rodents to humans problemat-
ic. Apart from data from a small number of ex vivo studies 
(i.e., perfused placenta) we know next to nothing about the 
ability of human placenta to take up and transfer NPs to the 
embryo/fetus. As far as the authors are aware, there have 
been no studies where the developmental toxicity of NPs in 
non-human primates and mammals other than rodents has 
been investigated.
Several problems and largely unanswered questions have to 
be addressed before tracing a roadmap to a research strategy, 
or tiered test battery scheme, to uncover potential develop-
mental health hazards posed by new nanotechnology products.
One of the biggest difficulties to be faced is that the nano-
materials already in use, and those undergoing development, 
encompass a broad diversity of NPs. As highlighted by Clark 
et al. 90, even within a single class of engineered NPs, such as 
carbon-based or metal oxide NPs, there exist “a wide range of 
sizes and shapes, with different chemical compositions and 
surface modifications, all of which may affect behavior and 
toxicity”. It therefore seems unfeasible to assess reproductive 
and developmental hazards by testing manufactured NPs on a 
case-by-case basis, particularly if in vivo mammalian tests are 
to be used. If a case-by-case approach is unrealistic, making 
generalizations about hazards posed by particular subsets of 
NPs is hindered by the limited experimental data so far avail-
able. Yet, our knowledge of the biological and toxic effects of 
this highly sophisticated and diverse group of materials is still 
too limited to make reliable generalizations based on classes, 
sizes, shapes or other features of NPs. In other words, if QSAR 
(Quantitative Structure Activity Relationship) computational 
models to identify reproductive and developmental hazards of 
single chemical molecules are still under construction 91, build-
ing up similar in silico predictive models to identify structural 
alerts (involving combinations of sizes, shapes, chemical com-
positions and other features) for NPs is probably unachievable 
in the near future.
Another difficulty is the heterogeneity in the size and the 
instability of some NPs in physiological solutions. As previously 
mentioned, under certain experimental conditions some NPs 
tend to agglomerate with time and it has been shown that 
toxicity (pulmonary toxicity, cytotoxicity and embryotoxicity) 
of fresh (predominantly singlet) NPs may at times differ from 
that of aged (predominantly agglomerated) NPs 49,92,93. Oxida-
tion of and ion release from metal NPs may also influence their 
toxicity.
Finally, an important difficulty in producing a roadmap for 
a testing strategy is the limited predictive value of in vitro 
(embryonic stem cells test) and ex vivo (zebrafish) assays, 
which are high throughput screening tests for detecting the 
developmental toxicity of NPs. The aforementioned in vitro 
and ex vivo tests cannot detect adverse effects on mammali-
an embryo development that arise indirectly from a maternal 
toxic effect and/or placental dysfunctions caused by NPs. It 
is of note that in tiered testing schemes, which are designed 
to save time and resources, a first step (tier) negative result 
tends to be definitive because as a rule the substance is not 
subsequently tested in vivo. However, a positive finding in the 
first tier in vitro or ex vivo assay generally leads to confirma-
tion in in vivo tests in rodents (second tier).
Differences between rodents and humans with respect 
to the structure and function of the placenta, particularly in 
early pregnancy, may eventually lead to false positive findings 
at this confirmatory testing step. Hence, more studies on the 
passage through and effects of NPs on human placental devel-
opment and functioning are needed.
In this review the authors’ focus was mainly on the eval-
uation of potential health hazards to development posed by 
engineered NPs, i.e., the first step (hazard identification) of 
risk assessment. Nonetheless it is worth mentioning that good 
quality data is also missing on quantitative estimations of hu-
man exposure (including women of childbearing age) to exis-
tent NPs and without this information it is impossible properly 
to assess and manage their health risks.
The identification of potential hazards and the assessment 
of human health risks posed by the myriad of novel nanotechnol-
ogy products is one of the challenges currently faced by toxicol-
ogists, particularly by those who deal with reproductive and de-
velopmental toxicology. Actually, any safe use of this fascinating 
novel technology in medicine and consumer products requires 
an equally innovative toxicological testing approach.
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